Home / Science / AI Fuels Biotech Leap: New Cures on Horizon
AI Fuels Biotech Leap: New Cures on Horizon
6 Feb
Summary
- AI accelerates drug discovery and gene editing for rare diseases.
- Companies use AI to find drug targets and design delivery vehicles.
- AI's role is expanding to virtual trials and personalized medicine.
Modern biotechnology is harnessing artificial intelligence to overcome long-standing challenges in drug discovery and gene editing, particularly for rare diseases. Companies are employing AI to enhance productivity and address talent shortages in the pharmaceutical sector.
Insilico Medicine utilizes its AI platform to ingest diverse data, generate hypotheses for disease targets, and identify potential drug candidates. This approach significantly reduces the time and cost associated with discovering and repurposing therapies, as seen in their work on ALS treatments.
GenEditBio is advancing in vivo gene editing with AI-driven delivery vehicles. Their proprietary ePDV technology, refined through machine learning, aims for precise, one-time injections of gene-editing tools directly into affected tissues, making treatments more affordable and globally accessible. The company is pursuing FDA trials for corneal dystrophy.
Both firms highlight the need for more comprehensive, unbiased data to train AI models effectively. Future advancements include creating digital twins of humans for virtual clinical trials, which could accelerate the approval of new therapeutic options and enable personalized treatments.
